Inactivating point mutations and deletions of the ETS factor ERF were recently identified in about 4% of prostate tumors, and these mutations are able to recapitulate phenotypes of ERG overexpression; furthermore, ChIP-seq analyses indicate that ERF and ERG compete for binding throughout the genome [17]. The gene discussed is ERF; the disease is prostate neoplasm.